Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04983940
Other study ID # 20200971
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 18, 2021
Est. completion date April 6, 2023

Study information

Verified date November 2023
Source University of Miami
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate patient satisfaction with an oral testosterone agent, Jatenzo, compared to other forms of testosterone therapy.


Recruitment information / eligibility

Status Completed
Enrollment 41
Est. completion date April 6, 2023
Est. primary completion date April 6, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Voluntarily sign and date the study consent form(s) which have been approved by an Institutional Review Board (IRB). Written consent must be obtained prior to the initiation of any study procedures. 2. Males between 18 and 65 years of age. 3. Documented diagnosis of testosterone deficiency. 4. Prior treatment with testosterone therapy at the time of enrollment with adequate control of low testosterone symptoms. Serum total testosterone < 300 ng/dL on 2 measurements prior to the initiation of testosterone therapy. Patients must have completed an adequate washout period following prior testosterone therapy (4 weeks for gels and injection based therapies and 16 weeks for subcutaneous pellets). 5. Judged to be in good general health as determined by the principal investigator based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG). Exclusion Criteria: 1. History of significant sensitivity or allergy to androgens or product excipients. 2. Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up or abnormal ECG. 3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or International Prostate Symptom Score (I-PSS) score > 19 points. 4. Body mass index (BMI) = 40 kg/m2. 5. Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis including but not limited to: 1. Baseline hemoglobin > 16 g/dL 2. Hematocrit < 35% or > 50% 6. Poorly controlled blood pressure as defined by Systolic Blood Pressure (SBP) >150 or Diastolic Blood Pressure (DBP) > 90 on two separate measurements 7. Concurrent use of any prohibited medications that can affect testosterone levels or metabolism. 8. History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures. 9. History of any clinically significant illness, infection, or surgical procedure within 4 weeks prior to study drug administration. 10. History of stroke or myocardial infarction within the past 5 years. 11. History of, or current or suspected, prostate or breast cancer. 12. History of, or current or suspected, pituitary abnormality. 13. History of diagnosed, severe, untreated, obstructive sleep apnea. 14. History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years. 15. Receipt of any investigational product within 4 weeks or within 5 half-lives prior to the start of treatment. 16. Inability to understand and provide written informed consent for the study. 17. Considered by the investigator or the sponsor-designated physician, for any reason, that the subject is an unsuitable candidate to receive Jatenzo

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Jatenzo
237 mg soft gel capsule taken twice a day by mouth with food.

Locations

Country Name City State
United States University of Miami Miami Florida

Sponsors (2)

Lead Sponsor Collaborator
University of Miami Clarus Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Satisfaction as Measured by TSQM-9 (Global Satisfaction Domain) Treatment Satisfaction Questionnaire for Medication (TSQM-9) has three domains (Global, Convenience, and Effectiveness), each with a total score ranging from 0 to 100 with the higher score indicating higher patient satisfaction. Up to 6 months
Primary Hypogonadal Symptoms as Measured by qADAM Questionnaire Quantitative Androgen Deficiency in the Aging Male (qADAM) has a total score ranges between 10 (most symptomatic) and 50 (least symptomatic). Up to 6 months
Secondary Serum Testosterone Levels Serum testosterone levels measured in ng/dL analyzed from peripheral venous puncture blood draw Up to 6 months
Secondary Serum Estradiol Levels Serum estradiol levels measured in pg/mL analyzed from peripheral venous puncture blood draw. Up to 6 months
Secondary Hematocrit Levels Hematocrit levels measured as a percentage analyzed from peripheral venous puncture blood draw. Up to 6 months
Secondary PSA Levels Measured in ng/mL Prostate Specific Antigen (PSA) levels measured in ng/mL analyzed from peripheral venous puncture blood draw. Up to 6 months
See also
  Status Clinical Trial Phase
Completed NCT03313635 - Evaluation of Prealbumin Levels in Men With Low-T
Completed NCT03528538 - The Efficacy of Fenugreek Supplementation on Men's Health N/A
Completed NCT03091296 - Diurnal Testosterone Concentration
Completed NCT05019859 - Effects of a Low Carb Diet on Erectile Function and Serem Testosterone in Men With Metabolic Syndrome N/A
Completed NCT03282682 - Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male N/A
Terminated NCT03335254 - A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males Phase 1/Phase 2
Completed NCT00512707 - Effect of Testosterone in Men With Erectile Dysfunction Phase 4
Not yet recruiting NCT06343870 - Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME) Phase 3
Recruiting NCT06177002 - SARS-CoV-2, TESTOSTERONE AND MALE FRAGILITY
Recruiting NCT05096169 - Pharmacokinetic Evaluation of Serum Testosterone Concentrations After Administration of Clomiphene Citrate Phase 2
Withdrawn NCT02082197 - An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men Phase 3
Completed NCT00858650 - Registry of Hypogonadism in Men N/A
Not yet recruiting NCT05773183 - Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
Withdrawn NCT04717362 - The Effects of Natesto For Treatment Of Hypogonadism Early Phase 1
Not yet recruiting NCT04601233 - Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis Phase 4
Withdrawn NCT04414904 - Determining the Reproductive Health of Men Post-COVID-19 Infection
Completed NCT01963390 - Metabolomics During Testosterone Therapy
Recruiting NCT04460872 - Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury Phase 2
Not yet recruiting NCT04245527 - Use of Infrared Photomodulation for Hormonal Balance (Joovvin' for Hormonal Health) N/A
Completed NCT00494208 - TDSM- Testosterone Dose Response in Surgically Menopausal Women N/A